We conclude that PAKs play a crucial role in regulating the FGF1/PDE4D antilipolytic pathway, adipogenesis and IR, thereby highlighting their potential as therapeutic targets for T2D. The gene discussed is FGF1; the disease is type 2 diabetes mellitus.